Prolexys Pharmaceuticals, Inc.

Whitehead Institute for Biomedical Research

Columbia University

Cell Genesys, Inc.

Paul B Robbins

Longwu Qi

Robert Selliah

Sudhir R Sahasrabudhe

Raj Gopal Venkat

Brent R Stockwell

Moritz Von Rechenberg

John M Peltier

Richard C Mulligan

Lawrence K Cohen

John Jay Boniface

Lori F Rafield

Justin Savage

Brad Guild

Michael Pierce

Isabelle Riviere

Robert R Becklin

Cindy Lou Chepanoske

Keith Simmon

Eugene Y Zhen

Vladimir Kery

Keith Simmons

John M Pelter

Eugene Zhen

Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reducing the rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.

3-aryl-substituted quinazolones, and uses thereof

The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.

Quinoxaline derivatives as antitumor agents

The present invention provides a method for purifying a protein complex and the components comprising the complex from a cell, a cell or tissue lysate or a whole organism by employing a combined set of affinity tags of high affinity, specificity and ease of elution. The method involves using a protein or a peptide modified to contain one or more affinity tags separated by one or more specific protease cleavage sites to isolate any interacting proteins or fragments thereof. Specifically exemplified is a method employing a modified bait containing AviTag or GST and a removal tag of Hishexapeptide positioned proximal to the bait such that any excess bait can be efficiently removed from the purified complex yielding enriched interacting proteins prior to subjecting the complex for further identification of individual components. The identification of the proteins or fragments thereof contained in the protein complex will provide new targets for the identification of new pharmaceuticals and diagnostic tools.

Method for purification of a protein complex and identification of its components

Erastin and erastin binding proteins, and uses thereof

Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.

Retroviral gene therapy vectors and therapeutic methods based thereon

Growing community of inventors

Park City, UT, United States of America

Paul B Robbins